search
Back to results

A Randomized Study Evaluating Steroid Hormone Levels, Safety And Tolerability Of GW870086X In Healthy Volunteers

Primary Purpose

Asthma

Status
Completed
Phase
Phase 1
Locations
Australia
Study Type
Interventional
Intervention
GW870086X
Sponsored by
GlaxoSmithKline
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring GW870086X, inhaled, asthma, cortisol, pharmacokinetics, osteocalcin

Eligibility Criteria

18 Years - 45 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion criteria:

  • Healthy male subjects
  • Liver function tests normal
  • 18 - 45 years old
  • Non smoker
  • Can provide written informed consent
  • Available to complete the whole trial
  • Can use the inhalation device correctly
  • Able to read, understand and write English

Exclusion criteria:

  • Deemed suitable healthy subject
  • History to sensitivity to the study medication
  • Any history of breathing problems in adult life
  • Participated in another trial within 30 days or 5 half-lives of the new chemical entity
  • Exposed to more than 4 new chemical entities within 12 months
  • Donated >500 mL blood within 2 months of screening
  • Haemoglobin level < 13g/dl
  • Use of prescription or non-prescription drugs within 7 days of first dose
  • Taking drugs that significantly inhibit cytochrome P450 subfamily enzyme CYP3A4
  • Drinks more than 4 units a day or 28 units a week
  • Cannot use DISKHALER device correctly
  • Positive HepB, HepC within 3 months of screening
  • Positive HIV test
  • Positive pre study drug/alcohol screen
  • Significant cardiac conduction abnormalities
  • Risk of non-compliance

Sites / Locations

  • GSK Investigational Site

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

GW870086X

Arm Description

Outcomes

Primary Outcome Measures

Effect of GW870086X on cortisol levels (naturally produced steroid hormone) in the body during a single dose and after 3 days of dosing

Secondary Outcome Measures

Safety & tolerability measures: heart rate, blood pressure, ECG, safety laboratory tests, lung function
Total urinary free cortisol excretion
Serum osteocalcin weighted mean
Fasting glucose
mRNA steroid responsive gene panel
Plasma concentrations of GW870086X and GW870086X pharmacokinetic parameters (including AUC, Cmax, t1/2 and tmax).
Plasma concentrations of GW870086X and derived pharmacokinetic parameters
Cortsiol urine concentrations
Osteocalcin serum concentrations

Full Information

First Posted
October 24, 2007
Last Updated
February 2, 2017
Sponsor
GlaxoSmithKline
search

1. Study Identification

Unique Protocol Identification Number
NCT00549497
Brief Title
A Randomized Study Evaluating Steroid Hormone Levels, Safety And Tolerability Of GW870086X In Healthy Volunteers
Official Title
A Randomized, Double-blind, Placebo-controlled, Dose Ascending, 3-cohort Parallel Group Study to Measure the Systemic Cortisol Profile and Evaluate the Safety, Tolerability and Pharmacokinetics of GW870086X, Administered as Single Doses (12mg and 15mg), and Repeat Doses Over 3 Days (6mg, 12mg and 15mg) in Healthy Male Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
February 2011
Overall Recruitment Status
Completed
Study Start Date
September 2007 (Actual)
Primary Completion Date
January 2008 (Actual)
Study Completion Date
January 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
GW870086X is a novel inhaled steroid that has an improved safety profile over other steroids but is also less potent. This study will look at higher doses to confirm the improved safety profile.
Detailed Description
A randomized, double-blind, placebo-controlled, dose ascending, 3-cohort parallel group study to measure the systemic cortisol profile and evaluate the safety, tolerability and pharmacokinetics of GW870086X, administered as single doses (12mg and 15mg),and repeat doses over 3 days (6mg, 12mg and 15mg) in healthy male subjects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
GW870086X, inhaled, asthma, cortisol, pharmacokinetics, osteocalcin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
Double
Allocation
N/A
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
GW870086X
Arm Type
Other
Intervention Type
Drug
Intervention Name(s)
GW870086X
Primary Outcome Measure Information:
Title
Effect of GW870086X on cortisol levels (naturally produced steroid hormone) in the body during a single dose and after 3 days of dosing
Time Frame
3 days
Secondary Outcome Measure Information:
Title
Safety & tolerability measures: heart rate, blood pressure, ECG, safety laboratory tests, lung function
Time Frame
3 days
Title
Total urinary free cortisol excretion
Time Frame
over 24 hours on Day 1 and Day 3.
Title
Serum osteocalcin weighted mean
Time Frame
over 24 hours on Day 3.
Title
Fasting glucose
Time Frame
on Day 1
Title
mRNA steroid responsive gene panel
Time Frame
3 days
Title
Plasma concentrations of GW870086X and GW870086X pharmacokinetic parameters (including AUC, Cmax, t1/2 and tmax).
Time Frame
3 days
Title
Plasma concentrations of GW870086X and derived pharmacokinetic parameters
Time Frame
3 days
Title
Cortsiol urine concentrations
Time Frame
3 days
Title
Osteocalcin serum concentrations
Time Frame
3 days

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria: Healthy male subjects Liver function tests normal 18 - 45 years old Non smoker Can provide written informed consent Available to complete the whole trial Can use the inhalation device correctly Able to read, understand and write English Exclusion criteria: Deemed suitable healthy subject History to sensitivity to the study medication Any history of breathing problems in adult life Participated in another trial within 30 days or 5 half-lives of the new chemical entity Exposed to more than 4 new chemical entities within 12 months Donated >500 mL blood within 2 months of screening Haemoglobin level < 13g/dl Use of prescription or non-prescription drugs within 7 days of first dose Taking drugs that significantly inhibit cytochrome P450 subfamily enzyme CYP3A4 Drinks more than 4 units a day or 28 units a week Cannot use DISKHALER device correctly Positive HepB, HepC within 3 months of screening Positive HIV test Positive pre study drug/alcohol screen Significant cardiac conduction abnormalities Risk of non-compliance
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
Herston
State/Province
Queensland
ZIP/Postal Code
4006
Country
Australia

12. IPD Sharing Statement

Citations:
PubMed Identifier
25614148
Citation
Dolle S, Hielscher N, Bareille PJ, Hardes K, Robertson J, Worm M. Clinical efficacy and tolerability of a novel selective corticosteroid in atopic dermatitis--two randomised controlled trials. Skin Pharmacol Physiol. 2015;28(3):159-66. doi: 10.1159/000367696. Epub 2015 Jan 20.
Results Reference
derived

Learn more about this trial

A Randomized Study Evaluating Steroid Hormone Levels, Safety And Tolerability Of GW870086X In Healthy Volunteers

We'll reach out to this number within 24 hrs